Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Gladstone Institutional Advisory LLC

Gladstone Institutional Advisory LLC trimmed its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 11.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 73,885 shares of the biotechnology company’s stock after selling 9,415 shares during the period. Gladstone Institutional Advisory LLC’s holdings in Sarepta Therapeutics were worth $8,984,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. Simplify Asset Management Inc. grew its holdings in Sarepta Therapeutics by 84.6% during the third quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock worth $24,105,000 after acquiring an additional 88,474 shares during the period. Geode Capital Management LLC grew its stake in shares of Sarepta Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after purchasing an additional 44,306 shares during the last quarter. Summit Partners Public Asset Management LLC raised its holdings in shares of Sarepta Therapeutics by 547.9% in the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock worth $17,250,000 after purchasing an additional 116,800 shares in the last quarter. Larson Financial Group LLC raised its holdings in shares of Sarepta Therapeutics by 1,649.8% in the 3rd quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock worth $1,093,000 after purchasing an additional 8,249 shares in the last quarter. Finally, abrdn plc lifted its stake in Sarepta Therapeutics by 30.7% during the third quarter. abrdn plc now owns 431,098 shares of the biotechnology company’s stock valued at $53,935,000 after purchasing an additional 101,253 shares during the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares of the company’s stock, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now owns 5,880 shares in the company, valued at approximately $738,234. This trade represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on SRPT. Evercore ISI decreased their price target on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Robert W. Baird decreased their target price on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $182.00 target price on shares of Sarepta Therapeutics in a research report on Monday, October 21st. StockNews.com lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a research note on Monday, January 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $176.77.

Sarepta Therapeutics Trading Down 2.7 %

NASDAQ SRPT opened at $109.68 on Wednesday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 1-year low of $102.15 and a 1-year high of $173.25. The firm’s fifty day simple moving average is $120.49 and its 200-day simple moving average is $125.33. The company has a market capitalization of $10.48 billion, a PE ratio of 87.74 and a beta of 0.75.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.